Dataset Information


EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.

ABSTRACT: Previously, it was shown that a novel 4-(N)-stearoyl gemcitabine nanoparticle formulation was more effective than gemcitabine hydrochloride in controlling the growth of model mouse or human tumors pre-established in mice. In the present study, the feasibility of targeting the stearoyl gemcitabine nanoparticles (GemC18-NPs) into tumor cells that over-express epidermal growth factor receptor (EGFR) to more effectively control tumor growth was evaluated. EGFR is over-expressed in a variety of tumor cells, and EGF is a known natural ligand of EGFR. Recombinant murine EGF was conjugated onto the GemC18-NPs. The ability of the EGF to target the GemC18-NPs to human breast adenocarcinoma cells that expressed different levels of EGFR was evaluated in vitro and in vivo. In culture, the extent to which the EGF-conjugated GemC18-NPs were taken up by tumor cells was correlated to the EGFR density on the tumor cells, whereas the uptake of untargeted GemC18-NPs exhibited no difference among those same cell lines. The relative cytotoxicity of the EGF-conjugated GemC18-NPs to tumor cells in culture was correlated to EGFR expression as well. In vivo, EGFR-over-expressing MDA-MB-468 tumors in mice treated with the EGF-conjugated GemC18-NPs grew significantly slower than in mice treated with untargeted GemC18-NPs, likely due to that the EGF-GemC18-NPs were more anti-proliferative, anti-angiogenic, and pro-apoptotic. Fluorescence intensity data from ex vivo imaging showed that the EGF on the nanoparticles helped increase the accumulation of the GemC18-NPs into MDA-MB-468 tumors pre-established in mice by more than 2-fold as compared to the un-targeted GemC18-NPs. In conclusion, active targeting of the GemC18-NPs into EGFR-over-expressed tumors can further enhance their anti-tumor activity.


PROVIDER: S-EPMC3253326 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC3236813 | BioStudies
2013-01-01 | S-EPMC3683387 | BioStudies
2012-01-01 | S-EPMC3419313 | BioStudies
2013-01-01 | S-EPMC3552003 | BioStudies
2014-01-01 | S-EPMC3993932 | BioStudies
2018-01-01 | S-EPMC6252274 | BioStudies
2008-01-01 | S-EPMC2590673 | BioStudies
2019-01-01 | S-EPMC6401407 | BioStudies
1000-01-01 | S-EPMC5105135 | BioStudies
2018-01-01 | S-EPMC6066187 | BioStudies